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A change in the study evaluation paradigm
reveals that larynx preservation
compromises survival in T4 laryngeal
cancer patients
Gerhard Dyckhoff1* , Peter K. Plinkert1 and Heribert Ramroth2
Abstract
Background: Larynx preservation (LP) is recommended for up to low-volume T4 laryngeal cancer as an
evidence-based treatment option that does not compromise survival. However, a reevaluation of the current
literature raises questions regarding whether there is indeed reliable evidence to support larynx preservation
for T4 tumor patients.
Methods: In an observational cohort study of 810 laryngeal cancer patients, we evaluated the outcomes of
all T4 tumor patients treated with primary chemo-radiotherapy (CRT) or primary radiotherapy alone (RT)
compared with upfront total laryngectomy followed by adjuvant (chemo)radiotherapy (TL + a[C]RT).
Additionally, we reevaluated the studies that form the evidence base for the recommendation of LP for
patients with up to T4 tumors (Pfister et al., J Clin Oncol 24:3693–704, 2006).
Results: The evaluation of all 288 stage III and IV patients together did not show a significant difference in
overall survival (OS) between CRT-LP and TL + a(C)RT (hazard ratio (HR) 1.23; 95% confidence interval (CI): 0.
82–1.86; p = 0.31) using a multivariate proportional hazard model. However, a subgroup analysis of T4 tumor
patients alone (N = 107; 13.9%) revealed significantly worse OS after CRT compared with TL + a(C)RT (HR 2.0;
95% CI: 1.04–3.7; p = 0.0369). A reevaluation of the subgroup of T4 patients in the 5 LP studies that led to
the ASCO clinical practice guidelines revealed that only 21–45 T4 patients had differential data on survival
outcome. These data, however, showed a markedly worse outcome for T4 patients after LP.
Conclusions: T4 laryngeal cancer patients who reject TL as a treatment option should be informed that their chance
of organ preservation with primary conservative treatment is likely to result in a significantly worse outcome in terms
of OS. Significant loss of survival in T4 patients after LP is also confirmed in recent literature.
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Background
In the landmark larynx preservation (LP) studies [1–3],
common practice has been to investigate and evaluate
locally advanced stage III and IV cancers of the larynx or
hypopharynx together. These groups comprise T4 car-
cinoma as well as T2 and T3 cancers. The results of
these studies led to the American Society of Clinical
Oncology (ASCO) 2006 clinical practice guidelines for
the use of larynx preservation strategies [4]. These
guidelines recommend that “for most patients with T3
or T4 disease without tumor invasion through cartilage
into soft tissues, a larynx preservation approach is an ap-
propriate, standard treatment option, and concurrent
chemo-radiotherapy is the most widely applicable ap-
proach.” [4] Furthermore, they state that with “further
surgery reserved for salvage, survival is not compro-
mised.” [4] These guidelines are currently the official
standard for avoiding total laryngectomy, particularly in
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the United States [5], as recent reviews have reconfirmed
[6–9]. Thus, in patients with early T4 disease, LP is ex-
plicitly recommended. According to the current Na-
tional Comprehensive Cancer Network (NCCN)
treatment guidelines, concurrent chemoradiation should
be considered only for “selected T4a patients who de-
cline surgery” [10]. As a result, one might expect that
only a minority of carefully selected T4a laryngeal cancer
patients are treated using primary conservative treat-
ment. However, nearly two-thirds of patients with T4a
disease undergo LP chemo-radiation [11].
We evaluated the outcomes of all T4 laryngeal cancer
patients between 1998 and 2004 in a study region cover-
ing a population of approximately 2.7 million people
with a follow-up of up to 17 years.
Motivated by the poor outcome after LP in this sub-
group, we reevaluated the literature cited in the ASCO
2006 guidelines to investigate whether there is indeed
reliable evidence of equal survival in T4 laryngeal cancer
patients who receive primary chemo-radiotherapy (CRT)
or radiation therapy alone (RT) compared with those
who undergo upfront total laryngectomy (TL).
Furthermore, we searched the literature for studies
published since 2006 providing evidence of the out-
comes of T4 laryngeal cancer patients after LP compared
with primary surgical treatment.
Methods
From 1998 to 2004, all laryngeal cancer patients (N = 810)
treated in the Southwestern region of Germany (covering
a population of 2.7 million people) were identified as part
of an observational cohort study and followed for at least
10 years. In this region, laryngeal cancer is exclusively
treated in the clinics from which the cases were obtained.
Local practitioners were also contacted to identify possible
cases sent to more distant clinics and to verify complete
case ascertainment.
Demographic data and clinical information were ex-
tracted from hospital medical records using a standard-
ized form. Vital status and date and cause of death were
requested from local registries.
Overall survival (OS) rates were calculated using the
Kaplan–Meier method. Regression analysis was per-
formed using multivariate proportional hazards models.
The overall survival rates of CRT and RT, both with the
option of salvage TL, were compared with those of sur-
gery (i.e., upfront TL in T4 cases) with adjuvant radio-
therapy or adjuvant chemo-radiotherapy, as indicated by
stage (TL+/-a[C]RT). Survival time was measured as the
time from the first diagnosis until death or until 21
March 2015. For the analysis, patients who migrated out
of Germany were censored after 1 month of emigration.
Only OS estimates are presented. P-values below 0.05
were considered statistically significant.
The following variables, which showed an effect in the
univariate analysis (p < 0.20), were included in the multi-
variate analysis as explanatory variables: age at first diag-
nosis (continuous), tumor location, TNM classification,
comorbidities, recurrences and second primary carcin-
omas and therapy approach. Backward selection was used
to obtain a final model. Proportional hazards assumption
was checked by adding a time-dependent version of all the
variables in the model [12]. The assumption was met for
all variables. The metastatic status could not be evaluated
as M1 status could be clearly determined for only 5 pa-
tients. Comorbidity conditions were determined using the
Charlson comorbidity index (CCI), which summarizes 18
different comorbidities, weighted by severity, in a single
score [13]. For this analysis, we considered the binary
form of the variable, which is set to one for CCI values of
two or higher. The development of local or regional recur-
rence or a second primary carcinoma (SPC) was included
in the model as a time-dependent covariate. For the date
of diagnosis of a recurrence or an SPC, the corresponding
variable was set to one. SAS 9.4 statistical software was
used for all analyses.
Additionally, the literature quoted in the ASCO 2006
guidelines as the evidence base for recommending LP
for patients with up to T4 cancer was reevaluated. Ac-
cording to the classical meaning, LP studies were de-
fined as those that included either advanced-stage
laryngeal or hypopharyngeal cancers that require or are
amenable to laryngectomy and are treated with LP as an
alternative to TL. To the extent that the available data
permitted, we checked i.) the number of T4 patients
who eventually received primary conservative treatment
compared with those who had been assigned to the con-
servative treatment arm and ii.) the outcomes of this
subgroup. A further literature search was conducted to
identify the studies that have investigated the treatment
of T4 laryngeal patients to date.
Results
During the seven-year recruitment period, 810 laryngeal
cancer patients were identified. For the current analyses,
41 patients were excluded as they either received no
treatment with curative intent (n = 28) or their tumor
stage was unknown (n = 13).
The median follow-up time for the remaining 769 pa-
tients was 8.3 years, with a range from 14 days to
16.8 years.
A subgroup of 288 patients (37.5%) was classified as
advanced stage and received treatment with curative
intent. The subgroup included 119 stage III (15.5%)
and 169 stage IV (22.0%) patients. Most of those pa-
tients were treated with surgery (n = 238); 30 (10.4%)
were treated with CRT, and 20 (6.9%) were treated
with RT alone. Additional information regarding the
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demographic and clinical characteristics of the three
treatment groups is provided in Table 1.
Our evaluation revealed that when the stage III and
stage IV patients were considered together, the patients
who received CRT had a non-significantly worse outcome
in terms of OS than those who underwent upfront TL
(Fig. 1a). The corresponding multivariate Cox propor-
tional hazard analysis showed a difference in OS between
the RT and the surgery group (HR 1.92; 95% CI: 1.16–
3.19; p = 0.0117) but no significant difference in survival
between the CRT and the immediate surgery group (HR
1.23; 95% CI: 0.82–1.86; p = 0.31).
However, the Kaplan Meier curve for the subgroup of
T4 carcinoma patients (N = 107; 13.9%) revealed severely
compromised survival after conservative LP (log-rank test:
p-value < 0.0001, Fig. 1b). This was confirmed with the
multivariate Cox proportional hazard analysis: Not only
was OS worse after RT compared with the immediate sur-
gery group (HR 4.6; 95% CI: 2.1–9.8; p = 0.0001), but
more importantly, survival was also worse after CRT (HR
2.0; 95% CI: 1.04–3.7; p = 0.0369) (Table 2). Approxi-
mately 90% of the T4 patients died within 1 year after RT
and within 2.5 years after CRT. Not a single T4 patient
survived 7 years after primary conservative therapy,
whereas the 10-year OS was 20% after TL + aR(C)T (95%
CI: 9%–28%).
In the 179 references cited as evidence in the ASCO
guidelines, five classical LP studies were found. Four of
these five studies included T4 cancer patients. Differen-
tial outcome data on treated T4 tumor patients were
presented in three of these four studies. In one of these
three studies, the number of patients who did not re-
spond to induction chemotherapy was not given. These
patients were part of the conservative treatment arm but
received upfront TL + adjuvant radiotherapy. Thus, the
exact number of T4 patients in the conservative treat-
ment arm of that study who eventually received conser-
vative treatment was unclear. Thus, differential outcome
data were presented for only 21–45 T4 tumor patients.
These data, however, show a markedly worse outcome
for the T4 subgroup (Table 3).
Discussion
In the observational study, survival among T4 patients
was significantly worse when their larynx was not re-
moved as part of the primary treatment regimen. This
result contrasts with the 2006 ASCO clinical guidelines’
statement that LP methods result in equal survival com-
pared with primary surgery. Although the number of T4
patients in the CRT and RT groups was small, the data
present the outcome of a representative cohort of all la-
ryngeal cancer patients within a population of 2.7 mil-
lion inhabitants.
Hospital records were used to extract data on disease-
specific characteristics, socio-demographic variables of
the study population and any events after diagnosis. The
presence of comorbidities in 28.6% of the patients is
likely to be an underestimation as information about co-
morbidities might be collected differently by physicians
Table 1 Demographic and clinical characteristics of the three
treatment groups
Charactersitic Category OP+/−a(C)RT
N (%)
CRT
N (%)
RT
N (%)
Total 684 (100) 40 (100) 45 (100)
Age (continuous)a 61.9 (9.7) 61.2 (11.1) 64.6 (9.8)
Sex Males 626 (91.5) 33 (82.5) 36 (80.0)
Females 58 (8.5) 7 (17.5) 9 (20.0)
CCI 0 494 (72.2) 33 (82.5) 22 (48.9)
1 100 (14.6) 1 (2.5) 15 (33.3)
2 63 (9.2) 5 (12.5) 6 (13.3)
3+ 27 (3.9) 1 (2.5) 2 (4.4)
Tumour location glottic 435 (63.6) 8 (20.0) 23 (51.1)
supraglottic 168 (24.6) 22 (55.0) 14 (31.1)
subglottic 13 (1.9) 1 (2.5) 1 (2.2)
transglottic 42 (6.1) 6 (15.0) 3 (6.7)
unknown 26 (3.8) 3 (7.5) 4 (8.9)
Stage I 304 (44.4) 3 (7.5) 10 (22.2)
II 142 (20.8) 7 (17.5) 15 (33.3)
III 103 (15.1) 10 (25.0) 6 (13.3)
IV 135 (19.7) 20 (50.0) 14 (31.1)
T stage 1 319 (46.6) 5 (12.5) 12 (26.7)
2 176 (25.7) 11 (27.5) 18 (40.0)
3 103 (15.1) 11 (27.5) 7 (15.6)
4 86 (12.6) 13 (32.5) 8 (17.8)
N stage 0 528 (77.2) 20 (50.0) 30 (66.7)
1 40 (5.8) 3 (7.5) 4 (8.9)
2 75 (11.0) 12 (30.0) 8 (17.8)
3 3 (0.4) 3 (7.5) 2 (4.4)
unknown 38 (5.6) 2 (5.0) 1 (2.2)
Grading 1 47 (6.9) 1 (2.5) 3 (6.7)
2 420 (61.4) 16 (40.0) 16 (35.6)
3,4 118 (17.3) 5 (12.5) 7 (15.6)
0, x 99 (14.5) 18 (45.0) 19 (42.2)
Laser 452 (66.1) − −
Partial resection 59 (8.6) − −
TL 173 (25.3) − −
RT Primary − − 45 (100)
Adjuvant 145 (21.2) − −
RCT Primary − 40 (100) −
Adjuvant 22 (3.2) −
aMean (Std.Dev)
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in different hospitals. Although validity could not be
verified, the comorbidities recorded at the time of diag-
nosis should present a non-differential bias at the most
and therefore should not have led to an overestimation
of the real effect or interfered with the other variables in
our analysis.
The Veterans Affairs Laryngeal Cancer Study Group
(VALCSG) and the European Organization for Research
and Treatment of Cancer (EORTC) trials proved that LP
with induction chemotherapy followed by radiotherapy
(ICRT) was feasible for advanced laryngeal and hypophar-
yngeal cancer patients without jeopardizing survival [1, 2].
However, the question is whether these large, randomized
trials yielding level I evidence [9] provide sufficient evidence
that LP is as appropriate for early T4 patients as for T3 pa-
tients, as stated in the 2006 ASCO guidelines. In the
EORTC hypopharyngeal trial, [2] induction chemotherapy
(ICT) served as stratifier for patients who might profit from
mere conservative treatment. Not a single T4 disease pa-
tient responded to ICT with complete remission. Thus, no
T4 patient in this study received primary RT, but all of
them were treated with upfront TL and aRT. The VALCSG
laryngeal cancer study [1] is the largest prospective ran-
domized controlled trial to date of laryngeal cancer
patients; it included 332 stage III and IV patients, with 42
and 43 T4 patients in the two treatment arms. In total, 59
of the 116 patients in the conservative arm underwent TL:
30 before and 29 after RT. “Salvage laryngectomy was re-
quired, however (…) in 56 percent of the patients with T4
cancers compared with 29% of patients with smaller pri-
mary tumors (p=0.0001).” [1]. Further multivariable analysis
in 1999 revealed that T4 tumors had a 5.6-fold lower likeli-
hood of responding to chemotherapy than T1–3 tumors
(95% CI, 1.5–20.8; p = 0.0108) [14]. The full multivariate
model for predicting LP in patients treated with ICRT
showed that T4 patients had a 7.1-fold worse organ preser-
vation rate than T1–3 patients (95% CI, 1.7–29.5;
p = 0.0070) [14]. In other words, T4 tumor patients had a
markedly higher risk of failure after ICRT.
The Groupe d’Etude des Tumeurs de la Tête et du
Cou (GETTEC) study [15] included only T3 laryngeal
carcinoma patients. Although these patients’ tumors
were less advanced than T4, 21 of the 36 patients in the
ICT group were treated with TL (58%), and despite sal-
vage TL, “survival and disease-free survival were signifi-
cantly worse in the induction chemotherapy group than
in the no chemotherapy group (p=0.006 and p=0.02, re-
spectively)” [15]. Richard concluded that “larynx
Fig. 1 a Kaplan Meier curves of stage III and stage IV patients by therapy group (OS); b Kaplan Meier curve for T4 carcinoma patients by therapy
group (OS)
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preservation for patients selected on the basis of having
responded to ICT cannot be considered a standard treat-
ment at the present time.” [15] Consistently, the GET-
TEC study was stopped because of these poor results for
patients with fixed cord cancer [16]. Although fixation
of the vocal cord does not surpass the T3 criteria, Horn
interpreted the poor results as a logical consequence of
tumors with a worse prognosis per se [6]. These results
suggest that LP might reach its limits of efficacy even in
less advanced stages than T4.
In the Bhalavat study [17], there were only two pa-
tients with a T4 tumor in the radiotherapy arm
Table 2 Univariate and multivariate Cox proportional hazard analysis results for all T4 patients (N = 107), 1998–2015
Characteristic Category Deceased Survived HR
(crude)a,b
95%-CI
(crude)a,b
p-valueb HR
(adjusted)a,c
95%-CI
(adjusted)a,c
p-valuec
Therapy TL + a(C)RT 74 (77.9) 12 (100) 1 - - 1 - -
CRT 13 (13.7) 0 (0.0) 3.0 (1.6, 5.6) 0.0004 2.0 (1.04, 3.7) 0.0369
RT 8 (8.4) 0 (0.0) 4.2 (2.0, 8.9) 0.0002 4.6 (2.1, 9.8) 0.0001
Aged (10 year units) 1.3 (1.1, 1.6) 0.0085 1.4 (1.1, 1.7) 0.0014
Recurrences No 74 (77.9) 12 (100) 1 - - 1 - -
Yes 21 (22.1) 0 (0.0) 8.5 (5.1, 14.7) <.0001 7.3 (4.1, 12.9) <.0001
N-stage N0,N1 56 (58.9) 10 (83.3) 1 - - 1 - -
N2,N3 39 (41.1) 2 (16.7) 2.2 (1.5, 3.4) 0.0002 1.6 (1.0, 2.5) 0.0489
Tumour location glottic 18 (18.9) 0 (0.0) 1 - -
supraglottic 34 (35.8) 4 (33.3) 0.75 (0.42, 1.3) 0.3282
subglottic 6 (6.3) 2 (16.7) 0.62 (0.24, 1.6) 0.3067
transglottic 26 (27.4) 3 (25.0) 0.74 (0.40, 1.4) 0.3300
Unknown 11 (11.6) 3 (25.0) 0.71 (0.33, 1.5) 0.3706
CCIe None 56 (58.9) 11 (91.7) 1 - -
One and
more
39 (41.1) 1 (8.3) 1.8 (1.2, 2.7) 0.0061
2nd primary
carcinoma
None 88 (92.6) 11 (91.7) 1 - -
Yes 7 (7.4) 1 (8.3) 1.3 (0.60, 2.9) 0.4857
aHR: Hazard Ratio; CI: Confidence interval; bResults from univariate analysis; cResults from multivariate analysis using backward selection; dcontinuous, eCCI:
Charlson Comorbidity Index
Table 3 Summary of patient outcomes in 5 studies comparing LP and TL in advanced laryngeal tumors
Study T4 patients assigned to
conservative treatment arm
T4 patients eventually treated
by primary CRT or RT
Comments
VALCSG [4, 14] 43 Unclear,
19 < N < 43
59 TL in 116 T1-T4 patients in the conservative treatment arm,
30 upfront
24 TL (upfront + salvage) in 43 T4 patients
TL in T4: 56%
TL in T1–3: 29%
T4 had 5.6-fold lower probability to achieve response to ICT
T4 had 7.1-fold poorer organ preservation rate than T1–3
EORTC [1] 4 0 No T4 patient in the chemo arm eventually received conservative
treatment, i.e. upfront TL followed by RT was the treatment for
all T4 patients in the surgery as well as in the chemo arm
GETTEC [15] 0 0 Only T3 patients were included
TL in 58% of patients of ICT arm
OS after CRT significantly poorer than after surgery (p = 0.006)
Bhalavat [16] 2 2 1 local recurrence after partial remission
1 survived for 5 years
RTOG 91–11
[2, 8, 17, 18]
18 ICRT
17 CCRT
16 RT
Unclear No T4 tumor with penetration through the cartilage, cartilage at
the most minimally eroded
7 upfront TL in ICRT
No data given about T category
No differential data given for T4
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compared with seven T4 patients in the primary surgery
arm. One of the two patients treated with RT relapsed
after a moderate response, while the other one survived
for 5 years. In contrast, the T4 patients treated with pri-
mary TL had a 5-year OS of 75%. However, it is impos-
sible to draw any reliable conclusions from these results.
The Intergroup RTOG 91–11 study was supposed to
show the non-inferiority of concomitant chemo-
radiotherapy (CCRT) compared with the VALCSG induc-
tion chemotherapy regimen (ICRT) [3]. Provided that the
OS outcome after ICRT was superior to that after CCRT,
non-responsiveness to induction chemotherapy might
identify the patients who require a more radical treatment
strategy than primary CRT alone (as was the case for all
the T4 patients in the EORTC study). The non-responders
in the ICRT arm received primary TL followed by RT and
thus were likely to have outcomes comparable to those of
the patients in the surgical arm of the VALCSG study;
however, this stratification was missing in the CCRT arm.
In the RTOG study, CCRT was superior to ICRT and RT
alone in terms of larynx preservation, and the five-year OS
estimates did not differ significantly. However, the recently
published long-term results showed 10-year OS rates of
38.8% and 27.5% in the ICRT and the CCRT groups, re-
spectively. Although it was not statistically significant
(p = 0.08; HR 1.25; 95% CI 0.98–1.61) [18], this strong ef-
fect cannot be ignored [8]. The RTOG study cohort con-
tained a mix of approximately 10% T2 patients, 30% T3
patients without cord involvement, 50% T3 patients with
fixed cord involvement, and only 10% T4 patients in each
group. Nonetheless, earlier-stage tumors have a much bet-
ter responsiveness to chemo-RT. Thus, a marked statisti-
cally significant difference could be anticipated if a T4
subgroup analysis were performed. However, a statistical
comparison among the T4 patients in the three treatment
arms was precluded, according to Forastière, as “only 10%
of patients enrolled in RTOG 91-11 had T4 cancers” [19].
There were 18, 17, and 16 T4 tumor patients in each arm
of the study and a huge number of other stage III and IV
patients with T2 and T3 tumors. Desirably, within the
same treatment arm, the outcome of this relatively small
number of T4 patients could be compared with those of
the large number of T2 and T3 patients. This subgroup
analysis might provide revealing level I evidence of the
outcome of T4 laryngeal cancer patients compared with
lower T stage patients after different types of LP.
In the RTOG 91–11 trial, the reported successful sal-
vage TL rates after CCRT and ICRT were 69% and 71%,
respectively [20]. The salvage TL success rate, however,
depends on the T category. Johansen reported a salvage
TL success rate of 79% for T1a, 68% for T2, 60% for T3
and only 44% for T4 glottic carcinoma [21]. Parsons re-
ported a success rate of 25% for T4 tumors compared
with 50% successful salvage TL for other T categories
[22]. Thus, the salvage TL success rate for T4 larynx car-
cinoma is not as favorable as the overall success rate of
approximately 70% reported for all T categories in the
RTOG 91–11 trial; instead, it is 25–50%.
In summary, the RTOG 91–11 does not prove the
non-inferiority of CCRT compared with ICRT in T4 lar-
ynx carcinoma in the absence of differential data for T4
patients. In the long run, the survival outcome after
CCRT was increasingly worse than after ICRT. After
10 years, the difference reached almost statistical signifi-
cance for the whole treatment arm, which comprised
T2, T3, and T4 tumors. This effect is probably more
pronounced in the subgroup of T4 tumor patients, who
were less responsive to CRT and had a worse outcome
with salvage surgery. Forastière stated in 2015 that in
her study, “no level I evidence supports a non-operative
organ preservation strategy for patients with T4a disease
and penetration through cartilage”. These patients were
not eligible for the RTOG 91–11 study; “only patients
with minimal cartilage erosion” were included [7], and
mere cartilage erosion is a notable criterion for a T3 dis-
ease in laryngeal cancer. In the other LP studies cited in
the ASCO guideline, a total of 21 to 45 T4 patients
eventually received primary conservative LP treatment
(see Table 2). Thus, the grade I evidence for LP in T4 in
these studies is based on a rather low number of pa-
tients. Additionally, in terms of differential results, the
T4 patients showed a markedly worse outcome after LP
compared with the other stage III and IV patients.
Shortly after the establishment of the ASCO guidelines
in 2006, some studies were published that supported our
finding that a conservative LP approach compromises
survival in T4 laryngeal cancer patients. Chen [23] eval-
uated the outcome of 10,590 patients with advanced la-
ryngeal cancer registered in a national hospital-based
cancer registry. Over 900 T4 tumor patients were treated
using a primary conservative approach (CRT, n = 358;
RT, n = 566), and 1690 patients were treated with up-
front TL + aRT. Among patients with stage IV disease,
TL was associated with significantly greater survival than
CRT or RT (p < 0.001) [23]. “Because the choice be-
tween chemo-RT and TL as optimal treatment for pa-
tients with T3 primary cancers is a matter of debate”
[23], Chen performed a separate proportional hazards
(PH) analysis for patients with T3 primary laryngeal can-
cers. T3 patients treated with CRT had a significantly in-
creased risk of death compared with those treated with
TL (HR = 1.18; p = 0.03). The effect was even more pro-
nounced for those treated with RT (HR = 1.59;
p = 0.001). Separate analyses of T4 patients were not
performed. In a large monocentric retrospective case
series of 451 patients, Gourin collected 50 primarily
non-surgically treated T4 patients compared with 77
surgically treated T4 patients over 17 years [24]. After
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controlling for nodal status, the authors found an in-
creased HR of death for patients treated with CRT (HR
2.0) or RT (HR 7.2) compared with TL + aRT. The 5-
year OS of these T4 tumor patients was significantly bet-
ter after TL + aRT (55%) than after CRT (25%) or RT
(0%; p < 0.0001) [24].
Accordingly, Olsen pronounced severe concern re-
garding the actual treatment of T4 laryngeal carcinoma
[16]. He especially stated that the distinction of “low-vol-
ume T4 tumors from T4 tumors” based on examination
or imaging “has not worked and is unproved” [16]. “Tu-
mors that extend through the laryngeal cartilage should
be treated with total laryngectomy” [16].
Five recent database studies corroborate the finding of
a significant loss of survival after LP in T4 patients. Gro-
ver investigated the outcome of 969 T4a laryngeal can-
cer patients, most (64%) of whom were treated with LP-
CRT [11]. He reported a markedly worse outcome for
patients treated with LP-CRT compared with patients
treated with upfront TL. “Median survival for TL versus
LP was 61 versus 39 months (p<0.001)” [11]. CRT
showed an inferior OS compared with TL (HR, 1.31;
95% CI 1.10–1.57) after potential confounders were con-
trolled [11]. Megwalu reported 5394 advanced-stage la-
ryngeal carcinoma that were treated between 1992 and
2009. During this period, the rate of non-surgical treat-
ment increased from 32% to 62%. The subgroup of
T4 N0 patients who received surgical treatment had a
better 5-year OS (56% vs. 38%; p < 0.001) than patients
who underwent non-surgical treatment, and this effect
was markedly more pronounced than that for T3 N0 pa-
tients (59% vs. 48%; p < 0.001) [25]. In multivariable ana-
lysis controlling for potential confounders, non-surgical
patients had worse OS (HR, 1.32; 95% CI, 1.22–1.43)
than surgically treated patients.
Evaluating 258 laryngeal cancer patients in a prospect-
ive longitudinal population-based cohort study, Dziegie-
lewski reported 5-year OS rates for T4a cancers of 70%
for TL + a(C)RT, 52% for CRT and 18% for RT. [26] The
HRs for RT and CRT compared with TL + a(C)RT were
4.9 (p < 0.001) and 2.3 (p = 0.04), respectively. It is
worth noting that in terms of tumor site, the patients
were “balanced with nearly a 50/50 glottic/supraglottic
split”, while in the VA and RTOG trials, there was a
heavy bias toward supraglottic tumors, which are well
known to respond better to CRT. Furthermore, patients
with increasingly advanced disease were treated with
TL + a(C)RT. Nevertheless, the surgically treated pa-
tients had a much better outcome. Moreover, Dziegie-
lewski called attention to the fact that the pivotal LP
trials were performed when the AJCC (5th edition until
2002) classified minor cartilage invasion tumors as T4
lesions. “These patients would be downstaged to T3 le-
sions by today’s standard” [26]. The exclusion of patients
with a low Karnofsky index, the inclusion of more supra-
glottic tumors, and the consequent restriction to T4 tu-
mors, e.g., those with “minimal thyroid cartilage
invasion or suspicion of invasion on imaging” per proto-
col in RCTs constitute “selection bias” [27]. Sanabria
critically states that the results of the randomized con-
trolled LP studies are more favorable than those of ob-
servational cohort studies and may not generally be
extrapolated to standard practice [27].
Timmermans reported the outcome of 1722 T4 laryn-
geal cancer patients treated in The Netherlands between
1991 and 2010 [28]. The difference in survival outcome
compared with the other three recent population-based
studies [11, 25, 26] was less marked but was statistically
significant: The 5-year OS after TL + a(C)RT, CRT and
RT was 48%, 42%, and 34%, respectively (overall
p < 0.0001) [28]. It is worth noting that the cohort com-
prised a considerable number of tumors that would be
classified as T3 according to today’s standard.
In a long-term retrospective analysis of 221 T4 pa-
tients (TL + a(C)RT; n = 161, CRT; n = 51, and RT;
n = 9), Rosenthal reported an initially superior locore-
gional control with upfront TL compared with LP (log-
rank p < 0.007) [29]. However, successful salvage surgery
resulted in an equal median survival time of 64 months
in the TL+(C)RT group as well as the LP groups. How-
ever, the preponderance of nodal positivity in the surgery
group must be taken in consideration (35.5% N2/3 in
the TL + aR(C) group vs. 11.5% in the LP group) as the
study revealed that node positivity represented the “pri-
mary determinant of mortality” (p < 0.0001) [29].
A recent database analysis presented the results of
3682 T4 M0 laryngeal cancer patients diagnosed from
2004 through 2012 [30]. Stokes divided the LP cohort
into ICRT and CCRT groups (TL + a(C)RT, n = 1599
compared with CCRT, n = 1597, and ICRT, n = 386).
The comparison between TL + a(C)RT and CCRT
strongly confirms the superiority of surgery over conser-
vative LP in T4 patients in terms of OS (HR, 1.55; 95%
CI 1.41–1.70, p < 0.01). The ICRT cohort was defined as
“undergoing RT plus multi-agent chemotherapy with
chemotherapy starting 43 to 98 days before RT” [30].
According to this definition, non-responders to IC and
patients discontinuing therapy due to death or no lethal
toxicity during the induction period were not included
in the ICRT cohort. As it is difficult to identify
intention-to-treat ICRT patients in a database analysis,
there is no evidence to date that ICRT might yield OS
results comparable to those of TL + a(C)RT.
In a systematic review, Francis retrieved 24 retrospective
studies reporting survival outcomes in T4 laryngeal cancer
patients. The 5-year OS outcome ranged from 10% to
80.9% for surgery, 16% to 50.4% for CRT, and 0% to 75%
for RT. However, due to major heterogeneity among the
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studies in terms of inclusion/exclusion criteria, laryngeal
subsite, neck staging and treatment protocols, no clear
conclusions can be drawn from these trials [31].
A multidisciplinary international consensus panel de-
veloped recommendations for conducting phase III clin-
ical trials of LP in patients with locally advanced
laryngeal and hypopharyngeal cancer. The panel expli-
citly considered whether patients with T4 disease should
be eligible for future organ preservation trials “because
these patients may suffer worse outcomes with this ap-
proach” [32]. This statement was supported by substan-
tial literature. According to the consensus panel, the
inclusion criteria for further LP studies are “T2 or T3 la-
ryngeal or hypopharyngeal SCC not considered for par-
tial laryngectomy” but not T4 carcinoma [32]. However,
the NCCN treatment guidelines state that while the first
recommendation for T4a tumor patients is laryngec-
tomy, concurrent chemoradiation should be considered
for “selected T4a patients who decline surgery” [10].
This recommendation is difficult for two reasons: 1.) Al-
most every patient will naturally reject laryngectomy if
offered possible organ preservation as an alternative, es-
pecially when preservation is mentioned in current
guidelines. 2.) The term “selected” implies that there
might be T4a tumors for which a conservative, larynx-
preserving treatment might be an appropriate approach.
Forastière claimed as recently as 2015 that “selected
low-volume T4 tumors endorse concomitant cisplatin
and RT on the basis of level I randomized controlled
trial data” [7]. As evidence, she quotes the 2006 ASCO
clinical practice guidelines for LP [4]. However, our re-
evaluation of the differential data from the T4 laryngeal
cancer patients in precisely these cited studies shows a
strong indication that this subgroup has a significantly
worse outcome when treated non-surgically. A meta-
analysis of the updated data of all T4 patients treated
with primary conservative LP in the cited studies com-
pared with the T2 and T3 patients in the same treatment
arms could further substantiate this finding.
In summary, the evaluation of the differential data
published in the large randomized controlled LP trials
for the subgroup of T4 tumor patients revealed that
CRT compromises survival in T4 laryngeal cancer pa-
tients. Until now, this effect was blurred by the evalu-
ation of all stage III and IV patients together in a group
that comprised T2, T3, and T4 patients. Recent large
retrospective database studies, a large series with con-
temporaneous controls, and our own observational co-
hort study have shown a statistically significant loss of
survival in T4 patients treated with conservative LP.
Conclusions
CRT and RT should no longer be recommended as
equivalent treatment options for T4 laryngeal cancer
patients, even in selected cases. T4 tumor patients who
definitively reject laryngectomy should be informed that
the possibility of larynx preservation with primary con-
servative treatment will likely result in a significantly
worse outcome in terms of overall survival. A statement
to this effect should be added to the NCCN guidelines.
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